Article

Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis

Université Catholique de Louvain, B-1200, Brussels, Belgium.
The Journal of Rheumatology (Impact Factor: 3.17). 11/2009; 37(1):141-8. DOI: 10.3899/jrheum.090411
Source: PubMed

ABSTRACT This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a randomized, double-blind trial.
Lumbar spine (LS), femoral neck (FN), and total hip (TH) BMD were measured at baseline and 18 months. Mean baseline glucocorticoid dose was categorized as low (< or = 5 mg/day), medium (> 5 and < 15 mg/day), or high (> or = 15 mg/day).
Baseline LS, FN, and TH BMD were similar between groups, and between glucocorticoid dose categories within each group. LS BMD increases at the low, medium, and high glucocorticoid doses were 8.1%, 6.6%, and 4.6%, respectively, with teriparatide, and 3.6%, 2.8%, and 2.3% with alendronate. Analyzed as a continuous variable, higher glucocorticoid doses had a negative, but non-significant, effect on the percentage increase in LS BMD in both groups. Glucocorticoid dose did not significantly affect FN or TH BMD increases in either group. Across the 3 glucocorticoid dose categories, the overall LS BMD increases were different for both treatments combined (p = 0.033), but the relative differences between the treatment groups were not different (interaction, p = 0.52).
Teriparatide and alendronate increased LS and hip BMD across a range of baseline glucocorticoid doses. LS BMD increases with teriparatide were greater in the low-dose category than in the high-dose category. Overall LS BMD increases were significantly greater with teriparatide compared with alendronate, which may reflect the respective anabolic and antiresorptive mechanisms of action. Clinical Trial Registry Number: NCT00051558.

0 Followers
 · 
70 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A bit-level pipelined 12×12-bit two's-complement multiplier with a 27-bit accumulator has been designed for applications in high-speed digital communication systems. A new quasi n-p domino logic structure has been investigated and adopted in this multiplier-accumulator design. When used in fully-pipelined circuits, this logic structure results in a much shorter propagation delay in comparison with conventional CMOS logic, pseudo-NMOS logic, and even standard n-p domino (NORA) logic. The chip complexity is approximately 10000 transistors, and the die area is 9.3 mm<sup>2</sup> in a 1.25-μ p-well CMOS technology. Based on SPICE simulations using conservative device parameters, the clock speed is projected to be over 150 MHz (i.e. >150 million multiply-accumulate operations per second), and the estimated power-speed ratio is 16 mW/MHz
    Computers and Communications, 1989. Conference Proceedings., Eighth Annual International Phoenix Conference on; 04/1989
  • [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis due to glucocorticoid-induced osteoporosis (GIOP) for inflammatory disorders continues to be a common problem. Well-distributed guidelines have provided evidence-based recommendations for management, yet many patients have little attention paid to their increased fracture risk. The purpose of this article is to discuss how new treatments for GIOP may improve overall management. Intravenous zoledronic acid (ZA), an antiresorptive agent, and teriparatide (TPT), which stimulates osteoblasts, have received US Food and Drug Administration (FDA) approval for treating GIOP. ZA is appealing because one 15-min infusion covers the patient for a year and potentially will increase the proportion of GIOP patients who are treated. TPT makes physiologic sense because GIOP is mostly due to decreased osteoblast function, and TPT stimulates osteoblasts. Although there is only one small published study in humans with GIOP, denosumab is a potentially useful antiresorptive agent, if it is approved by the FDA. The efficacy and safety of these medications in GIOP are discussed.
    Current Osteoporosis Reports 03/2010; 8(1):10-4. DOI:10.1007/s11914-010-0003-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis is characterized by the occurrence of a host of fractures. According to densitometric values, an operational definition for osteoporosis corresponds to a loss of 25% to 30% (-2.5 T-scores) compared with the mean values of bone mineral density of young premenopausal women. For years, research tried to develop drugs to improve the bone mineral density. According to the compounds, antiresorptive agents are able to decrease the fracture rate by about 30% to 70%, and to increase the bone mineral density. However, the agents increasing the most bone mineral density are not necessarily those that influence the most fracture rates. It has been known for years that parathyroid hormone (PTH) administered cyclically is able to increase bone mineral density. Two analogues of PTH have been developed: PTH (1-34) and PTH (1-84). Both of them are able to increase bone mineral density and reduce the rate of vertebral fracture but not of the hip, nor of nonvertebral fractures, the latter at least for PTH (1-84). Their exact place in the armamentarium of therapy of osteoporosis and their best time of administration are not yet definitely settled. New modes of administration (transdermal, intranasal, oral) will probably become available soon. With all the drugs available today and those still in development, it can be hoped that osteoporosis will become a disease of the past.
    Current Osteoporosis Reports 09/2010; 8(3):154-61. DOI:10.1007/s11914-010-0024-1